 Aeglea BioTherapeutics, Inc. AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced a new 56 week analysis on Arginase 1 Deficiency ARG1-D patients who have been treated with pegzilarginase from the Companys completed Phase 12 clinical trial and the ongoing Phase 2 open-label extension study. The data were shared yesterday in a virtual, late-breaking oral presentation at the 6th Congress of the European Academy of Neurology. 